Id |
Subject |
Object |
Predicate |
Lexical cue |
T225 |
0-37 |
Sentence |
denotes |
Activation of other receptors by SPMs |
T226 |
38-108 |
Sentence |
denotes |
A few studies have reported the possibility of other GPCR involvement. |
T227 |
109-217 |
Sentence |
denotes |
Among them, GPR101 mediates the pro-resolving effects of RvD5n-3 DPA in arthritis and infection (Flak et al. |
T228 |
218-224 |
Sentence |
denotes |
2020). |
T229 |
225-317 |
Sentence |
denotes |
Besides, SPMs have been reported to activate non-GPCRs receptors, such as nuclear receptors. |
T230 |
318-504 |
Sentence |
denotes |
In a dose-dependent manner, PD1 enhances PPARγ transcriptional activation reporter activity in human neuron-glia (HNG) cells co-transfected with hPPARγ-GAL4 and MH100-tk-Luc (Zhao et al. |
T231 |
505-511 |
Sentence |
denotes |
2011). |
T232 |
512-629 |
Sentence |
denotes |
This suggests that PD1 is capable of enhancing the peroxisome proliferator-activated receptor gamma (PPARγ) (Fig. 2). |
T233 |
630-728 |
Sentence |
denotes |
The transcriptional activity of PPARγ was significantly increased after treatment with 100 nM PD1. |
T234 |
729-960 |
Sentence |
denotes |
RvD1 was also assumed to be a ligand for PPARγ and inhibited IκBα degradation and NF-κB p65 nuclear translocation in an LPS-induced lung injury model, which was partially reversed by the PPARγ inhibitor GW9662 (Fig. 2) (Liao et al. |
T235 |
961-967 |
Sentence |
denotes |
2012). |
T236 |
968-1083 |
Sentence |
denotes |
Recently, it has been reported that LXA4 binds to the nuclear aryl hydrocarbon receptor (AhR) (Fig. 2) (Asha et al. |
T237 |
1084-1090 |
Sentence |
denotes |
2020). |
T238 |
1091-1153 |
Sentence |
denotes |
A GPCR that acts directly on MaR1 has not yet been identified. |
T239 |
1154-1476 |
Sentence |
denotes |
However, MaR1 blocks TRPV1-mediated currents in neurons, acts as a ligand for the retinoid-associated orphan receptor α (RORα), and inhibits TLR4 signalling (Fig. 2) (Park 2015), Chiang et al. found that MaR1 can activate LGR6, a member of the glycoprotein hormone receptor subfamily of rhodopsin-like GPCRs (Chiang et al. |
T240 |
1477-1620 |
Sentence |
denotes |
2019b), which initiates cAMP, impedance changes, and stimulate an innate immune response against PMNs, monocytes and macrophages (Chiang et al. |
T241 |
1621-1628 |
Sentence |
denotes |
2019b). |